Shunichi Hosoda
Overview
Explore the profile of Shunichi Hosoda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
55
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang Z, Suda G, Sho T, Maehara O, Ohara M, Yoda T, et al.
Hepatol Res
. 2024 Nov;
PMID: 39584803
Aim: Atezolizumab/bevacizumab is a first-line therapy for unresectable hepatocellular carcinoma (HCC). Among several adverse events, grade ≥2 proteinuria is considered a significant adverse event that may cause bevacizumab interruption. Studies...
2.
Yasuura N, Suda G, Ohara M, Meno A, Sho T, Kohya R, et al.
Aliment Pharmacol Ther
. 2024 Sep;
60(10):1315-1324.
PMID: 39228289
Background And Aims: The prognostic impact of previous-HBV-infection (pHBV) in non-HBV-related hepatocellular carcinoma (non-HBV-related-HCC) and the prevalence, characteristics and significance of recently developed high-sensitivity HBs antigen positivity (hHBsAg+) in these...
3.
Sho T, Suda G, Ohara M, Kohya R, Sasaki T, Yoshida S, et al.
Target Oncol
. 2024 Sep;
19(5):769-778.
PMID: 39222223
Background: While guidelines recommend immune checkpoint inhibitor (ICI) rechallenge as second-line therapy for unresectable hepatocellular carcinoma (HCC), data supporting this remain limited, particularly regarding a standard regimen for first- and...
4.
Ohara M, Suda G, Kohya R, Sasaki T, Yoda T, Yoshida S, et al.
Front Nutr
. 2023 Oct;
10:1272728.
PMID: 37867493
Introduction: We aimed to assess the prognostic implications of muscle atrophy and high subcutaneous adipose tissue (SAT) radiodensity in patients with hepatocellular carcinoma (HCC). Methods: In this retrospective study, muscle...
5.
Kohya R, Suda G, Ohara M, Sasaki T, Yoda T, Sakurai N, et al.
Cancers (Basel)
. 2023 Jun;
15(12).
PMID: 37370867
Lenvatinib, used for unresectable hepatocellular carcinoma (HCC), causes appetite loss, but the underlying mechanisms, clinical impact, and predictive factors have been unclear. The endocrine factor FGF21 modulates appetite and is...
6.
Sasaki T, Suda G, Ohara M, Hosoda S, Kawagishi N, Kohya R, et al.
Hepatol Res
. 2023 Jun;
53(10):960-967.
PMID: 37332115
Aim: Although hepatitis delta virus (HDV) coinfection with hepatitis B virus (HBV) is a global health concern, the global prevalence of HDV infections remains unknown due to insufficient data in...
7.
Hosoda S, Suda G, Sho T, Ogawa K, Kimura M, Yang Z, et al.
Liver Cancer
. 2023 Jun;
12(2):156-170.
PMID: 37325489
Introduction: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus...
8.
Nakai M, Morikawa K, Sasaki T, Kohya R, Yoshida S, Hosoda S, et al.
J Gastroenterol
. 2023 Apr;
58(7):656-667.
PMID: 37103575
Background: Acute kidney injury (AKI) is associated with liver cirrhosis (LC), water retention, diuretics to treat water retention, and a poor prognosis. Urinary neutrophil gelatinase-associated lipocalin (uNGAL) reportedly predicts a...
9.
Tokuchi Y, Suda G, Kawagishi N, Ohara M, Kohya R, Sasaki T, et al.
Hepatol Res
. 2023 Mar;
53(7):595-606.
PMID: 36945790
Aim: Hepatitis C virus (HCV) infection has been reported to cause liver steatosis. Thus, eradicating HCV with direct-acting antivirals (DAAs) is expected to reduce liver steatosis. We aimed to clarify...
10.
Yang Z, Suda G, Maehara O, Ohara M, Yoda T, Sasaki T, et al.
Cancers (Basel)
. 2023 Feb;
15(3).
PMID: 36765554
The possible mechanisms of resistance to atezolizumab/bevacizumab for unresectable HCC, and the subsequent response to these therapies, remain underexplored. The sequential changes in serum growth factors, including VEGF-A, VEGF-C, VEGF-D,...